Qianyuan Pharmaceutical Co., Ltd.

Board Secretary Work System (May 2026)

Announcement on Granting Reserved Restricted Stocks to Incentive Objects under the 2025 Restricted Stock Incentive Plan

Legal Opinion on Shanxi Qianyuan Pharmaceutical Group Co., Ltd. 2025 Annual Shareholders Meeting

Compensation and Assessment Committee's Review on the List of Reserved Grant Recipients for the 2025 Restricted Stock Incentive Plan

2025 Restricted Stock Incentive Plan Reserved Grant List (Reserved Grant Date)

Announcement of Resolutions from the 2025 Annual Shareholders' Meeting

Announcement on Share Buyback and Cancellation of Restricted Stock Reducing Registered Capital and Notifying Creditors

Legal Opinion on Granting of Reserved Shares in Shanxi Qianyuan Pharmaceutical Group's 2025 Restricted Stock Incentive Plan

Announcement of Resolutions from the Fifth Meeting of the Sixth Board of Directors

Notice of Annual Shareholders' Meeting for 2025

Announcement on Participation in 2026 Shanxi Listed Companies Investor Online Reception Day and Cancellation of 2025 Online Performance Briefing

Compensation Management System for Directors and Senior Executives (April 2026)

Announcement on Proposed Establishment of a Holding Subsidiary and Related Transactions

Notice of Disclosure for Q1 2026 Report

Notice of Disclosure for the 2025 Annual Report

Announcement on Adjustments to the Nomination Committee Members of the Sixth Board of Directors

2025 Annual Board of Directors Work Report

Pacific Securities Co., Ltd. Review Opinion on Delay of Certain Fundraising Projects

Announcement on the Reappointment of Audit Firm for 2026

Announcement of the 2026 Compensation Plan for Directors and Senior Management

2025 Annual Report of Independent Director (Fang Guowei)

2025 Annual Report of Independent Director (Gao Hao - Resigned)

2025 Annual Report of Independent Director (Huang Dong)

2025 Annual Report of Independent Director (Luo Zhukun)

2025 Annual Report of Independent Director (Wu Jinfeng)

2025 Annual Report of Independent Director (Yang Bo)

Announcement on the 2025 Online Performance Briefing

2025 Internal Control Audit Report

2025 Internal Control Evaluation Report

Compensation and Evaluation Committee Work Guidelines (April 2026)

Announcement on Changes to Registered Capital and Amendments to Articles of Association

Announcement on the Revision of the Board Committee Working Rules

Company Articles of Association (April 2026)

Work Regulations of the Innovation and Strategy Committee (April 2026)

Audit Committee Work Regulations (April 2026)

Nomination Committee Working Rules (April 2026)

Announcement on Company Losses Exceeding One-Third of Paid-in Capital

Announcement on Changes to Accounting Policies

Announcement on Asset Impairment Provision and Write-off for 2025

Legal Opinion on the Repurchase and Cancellation of Restricted Stock for Shanxi Qianyuan Pharmaceutical Group's 2025 Incentive Plan

Compensation and Assessment Committee's Review on Repurchase and Cancellation of Certain Restricted Stocks from 2025 Incentive Plan

Announcement on the Repurchase and Cancellation of Certain Restricted Stocks from the 2025 Incentive Plan

Pacific Securities Review Opinion on Fund Storage and Use for 2025

Verification Report on the Use and Storage of Fundraising for 2025

Announcement on the Postponement of Certain Fundraising Projects

Announcement on Estimated Routine Related Transactions for 2026

Announcement on Completion of Capital Increase and Related Transactions with Affiliates for Subsidiary

Notice of 2025 Annual Shareholders Meeting

Announcement of Resolutions from the Fourth Meeting of the Sixth Board of Directors

Special Statement on Proposed Non-Distribution of Profits for 2025

Q1 2026 Report

Special Report on Fundraising Storage and Usage for 2025

Pacific Securities Co., Ltd. Special Audit Report on Fundraising Storage and Usage for 2025

Company Evaluation Report on the Performance of Accounting Firm for 2025

Evaluation Report on the Performance of the Accounting Firm for 2025 by the Board Audit Committee

Special Report on Non-Operational Fund Occupation and Other Related Fund Transactions for 2025

Summary of Non-Operational Fund Occupation and Other Related Fund Transactions

Special Report on the Self-Assessment of Independent Directors' Independence by the Board of Directors

2025 Annual Audit Report

2025 Annual Report

Summary of the 2025 Annual Report

Announcement on the Progress of Acquiring Remaining Shares of Subsidiary Nantong Hengjia and Completion of Business Registration Changes

Legal Opinion on QianYuan Pharmaceutical's Second Extraordinary Shareholders' Meeting 2026 by GuoHao Law Firm (Shanghai)

Announcement of the Second Extraordinary Shareholders' Meeting Resolutions for 2026

Announcement on Progress of Bidding for Subsidiary Minority Equity and Completion of Business Registration Changes

Notice of the Second Extraordinary Shareholders' Meeting in 2026

Announcement on the Buyback and Cancellation of Certain Restricted Stocks from the 2025 Incentive Plan

Announcement on Completion of Business Registration Change and Issuance of New Business License

Announcement on Judicial Freezing of Shares Held by Major Shareholder Exceeding 5%

Announcement on Proposed Guarantee for Financing Lease Business of Wholly-Owned Subsidiary

Notice of the Second Extraordinary Shareholders' Meeting in 2026

Announcement of Resolutions from the Third Meeting of the Sixth Board of Directors

Announcement on Proposed Acquisition of Remaining Equity in Subsidiary Nantong Hengjia

Announcement on the Lifting of Judicial Freeze on Shares of Major Shareholder Holding Over 5%

Announcement on Auction for Acquisition of Minority Stake in Subsidiary

Announcement of Resolutions from the Second Meeting of the Sixth Board of Directors

Announcement on the Implementation of Share Reduction by Shareholders Holding Over 5%